Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Epidemiologic Notes and Reports Hepatitis A Among Drug Abusers

Over the past several years, CDC has received an increasing number of reports of hepatitis A outbreaks involving drug abusers. These outbreaks have occurred in many areas of the United States, including Alaska, Oregon, Washington State, northern and southern California, Oklahoma, upstate New York, and Connecticut. A variety of drugs have been used: in Oregon, northern California, and Oklahoma, intravenous (IV) amphetamines have been most commonly implicated; in one locality in southern California, a new form of heroin, referred to as "black tar" because of its color and consistency, has been linked with transmission; in upstate New York, IV cocaine has been the primary drug. In several areas, cases have occurred among people who only smoked marijuana. Outbreaks in upstate New York and northern California and data from the Viral Hepatitis Surveillance Program (VHSP)* are summarized below to illustrate this trend.

Upstate New York

Since December 1, 1986, hepatitis A outbreaks predominantly involving drug abusers have been reported in Monroe, Cortland, Onondaga, and Chemung counties in upstate New York. In Monroe County, 87 cases of physician-diagnosed hepatitis A were reported to local health authorities between December 1, 1986, and May 31, 1987 . An average of nine cases had been reported for the same period of the previous 2 years. Twenty-four (28%) of these patients were IV drug abusers without other identifiable risk factors for hepatitis A. Eight additional patients were sexual or household contacts of these 24 patients. Information about the specific drugs used was not available for all patients; however, local drug enforcement officials believe that cocaine is the primary drug used intravenously in Monroe County.

Thirty-eight cases of hepatitis A occurred in Cortland County in 1987. Twenty-two (58%) of the patients were known or suspected drug abusers. Eleven of these cases occurred between March 25 and April 18. About 1 month before becoming ill, these 11 patients had attended two different social gatherings at which seven of them had used IV cocaine and shared needles. No food was consumed nor were beverages shared at these gatherings, and no other risk factors for hepatitis A could be identified.

Increases in hepatitis A also occurred in Onondaga and Chemung Counties during 1987. Fifty (38%) of the 131 cases of hepatitis A in Onondaga County in 1987 were among known or suspected drug abusers; 70% of the 50 patients used only IV cocaine. Thirteen cases occurred between October and December in Chemung County. Four (31%) of these patients were drug abusers; all used IV cocaine only. Anecdotal information suggested that drug abusers in Chemung County had recently obtained cocaine from persons in Onondaga County.

Northern California

In June 1987, an outbreak of hepatitis A among patrons of a restaurant in a northern California county was reported to local health authorities. Investigation revealed that a restaurant cook with a history of IV drug abuse had been diagnosed with hepatitis A several weeks earlier. A review of all serologically confirmed cases of hepatitis A in the county between January 1 and June 30, 1987, was subsequently conducted. Thirty (42%) of the 71 cases identified were associated with the foodborne outbreak originating at the restaurant (Figure 1). Thirty-three of the remaining 41 patients were contacted either directly or through friends or family. Twenty-four (73%) of these 33 patients were IV drug abusers and did not have other risk factors for hepatitis A. Eleven (46%) of the IV drug abusers were male; all were white; and they ranged from 21 to 39 years of age. Twelve of the drug abusers admitted to IV drug use within 6 weeks before onset of hepatitis A. All twelve had injected "crank" (an amphetamine derivative). Twelve of the IV drug abusers admitted to either casual or intimate contact or sharing needles or drug paraphernalia with at least one other IV drug abuser who contracted hepatitis A during the same period.

Viral Hepatitis Surveillance Program

Data from VHSP indicate an increasing association between drug abuse and hepatitis A in the United States. Between 1982 and 1986, the percentage of persons with hepatitis A who admitted to previous IV drug use rose steadily from 4% to 19%. During this period, overall hepatitis A rates were relatively constant, and the proportion of patients with hepatitis A who had other identifiable risk factors remained stable. It should be noted, however, that only one-third of patients reported to the MMWR Morbidity Surveillance System were interviewed through VHSP and that only a modest proportion of such persons are routinely asked about IV or other drug use. Reported by: SA Jenkerson, MSM, JP Middaugh, MD, State Epidemiologist, Alaska Dept of Health and Social Svcs. SL Pittman, RS Hill, MD, Napa County Health Dept, Napa; AG Redeker, MD, Rancho Los Amigos Medical Center, Los Angeles; RR Roberto, MD, California Dept of Health Svcs. JL Hadler, MD, MPH, State Epidemiologist, Connecticut State Dept of Health Svcs. KM Bell, MD, Monroe County Dept of Health, Rochester; J Miller, MD, MPH, Onondaga County Health Dept, Syracuse; J Feuss, Cortland County Health Dept, Cortland; C Benjamin, Chemung County Health Dept, Elmira; S Kondracki, M Toly, DL Morse, MD, MS, State Epidemiologist, New York State Dept of Health. B Gildon, GR Istre, MD, State Epidemiologist, Oklahoma State Dept of Health. J Polder, RN, MPH, LR Foster, MD, MPH, State Epidemiologist, Oregon Dept of Human Resources. JM Kobayashi, MD, State Epidemiologist, Washington Dept of Social and Health Svcs. Div of Field Svcs, Epidemiology Program Office; Hepatitis Br, Div of Viral Diseases, Center for Infectious Diseases, CDC. Editorial Note: In the United States, transmission of hepatitis A has traditionally been associated with crowding, poor personal hygiene, improper sanitation, and, less commonly, contamination of food or water. Recognized risk factors include intimate or close contact with persons with hepatitis A, foreign travel to developing countries, and contact with children in day-care centers.

The association of drug use and hepatitis A has been recognized only recently. Well-documented outbreaks of hepatitis A among drug abusers have been reported in Scandinavian countries (1,2). In seroprevalence studies of antibodies against hepatitis A virus (HAV) in Denmark, drug abusers have had antibody rates four times those of the general population (3).

Two possible explanations for the association between hepatitis A and drug use have been proposed: 1) HAV may be transmitted by injection or ingestion** of contaminated drugs (common-source spread), or 2) transmission may result from direct person-to-person contact. The culture of fecal coliforms from marijuana confiscated during one investigation (Alaska Department of Health and Social Services, unpublished data) raises the possibility that direct contamination of drugs could be a factor in some of these outbreaks.*** Drugs could become contaminated with fecal material containing HAV at the cultivation site (e.g., through use of human feces as fertilizer) or during transport, preparation, or distribution (e.g., through smuggling in condoms concealed in the rectum (4) or in baby diapers). However, the pattern of occurrence of the cases by dates of onset in each of the outbreaks and the diversity of drugs involved argue against a single common-source mode of transmission. Nevertheless, sustained common-source transmission is possible if contaminated drugs were distributed among persons who then used them at different times.

Person-to-person transmission of HAV between drug abusers could result from sharing needles, from sexual contact, or from generally poor sanitary and personal hygiene conditions, which have often been observed among drug abusers. Isolated instances of bloodborne transmission resulting from transfusions from donors who had given blood during the incubation period of viral infection have been reported. Due to the relatively short viremic phase of HAV infection, however, bloodborne transmission through needle-sharing is unlikely to have sustained large outbreaks such as those reported here, although it may have accounted for one cluster in Cortland County.

Investigations of the various outbreaks to date have not revealed clear modes of transmission. It is possible that each outbreak has multiple modes of transmission. Physicians and public health authorities are strongly urged to identify and investigate hepatitis outbreaks among drug abusers. Clinicians evaluating persons with a history of drug use for viral hepatitis should obtain serologic tests for both hepatitis A and B. Public health officials should ask persons with hepatitis A about drug use and include such information on the VHSP questionnaires. Control measures include the use of good sanitation and personal hygiene and the administration of immune globulin to contacts of patients within 2 weeks of exposure. Factors operating in communities of drug abusers, such as poor hygienic conditions and transience as well as the relatively poor responsiveness of such groups to education and preventive efforts, make outbreaks among these groups difficult to control. Consequently, drug abusers may be candidates for the vaccines against HAV that are currently being developed (5,6). References

  1. Widell A, Hansson BG, Moestrup T, Serleus Z, Mathiesen LR, Johnsson T. Acute hepatitis A, B and non-A, non-B in a Swedish community studied over a ten-year period. Scand J Infect Dis 1982;14:253-9.

  2. Widell A, Hansson BG, Moestrup T, Nordenfelt E. Increased occurrence of hepatitis A with cyclic outbreaks among drug addicts in a Swedish community. Infection 1983;11:198-200.

  3. Scheutz F, Skinhoj P, Mark I. Viral hepatitis among parenteral drug addicts attending a Danish addiction clinic. Scand J Infect Dis 1983;15:139-43.

  4. Sundkvist T, Johansson B, Widell A. Rectum carried drugs may spread hepatitis A among drug addicts. Scand J Infect Dis 1985;17:1-4.

  5. Binn LN, Bancroft WH, Lemon SM, et al. Preparation of a prototype inactivated hepatitis A virus vaccine from infected cell cultures. J Infect Dis 1986;153:749-56.

  6. Provost PJ, Bishop RP, Gerety RJ, et al. New findings in live, attenuated hepatitis A vaccine development. J Med Virol 1986;20:165-75. *A nationwide reporting system in which patients serologically confirmed to have hepatitis A are interviewed to identify probable sources of illness. **By tasting the drug to assess quality, for example. ***HAV could not, however, be isolated from the marijuana by tissue culture (CDC, unpublished data).



Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.


All MMWR HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

 
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Road Atlanta, GA 30329-4027, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #